Cargando…
Novel opportunities for CFTR-targeting drug development using organoids
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR mutations lead to production of non-functional CFTR, reduced amounts of normal functioning CFTR or misfolded CFTR with defects in trafficking or function. For decades, CF treatmen...
Autores principales: | Dekkers, Johanna F, van der Ent, Cornelis K, Beekman, Jeffrey M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915567/ https://www.ncbi.nlm.nih.gov/pubmed/25003014 http://dx.doi.org/10.4161/rdis.27112 |
Ejemplares similares
-
CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes
por: Lefferts, Juliet W., et al.
Publicado: (2023) -
Drug Repurposing for Cystic Fibrosis: Identification of Drugs That Induce CFTR-Independent Fluid Secretion in Nasal Organoids
por: Rodenburg, Lisa W., et al.
Publicado: (2022) -
CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy
por: de Poel, Eyleen, et al.
Publicado: (2021) -
CFTR Expression Analysis in Human Nasal Epithelial Cells by Flow Cytometry
por: van Meegen, Marit A., et al.
Publicado: (2011) -
Imprimatins A and B: Novel plant activators targeting salicylic acid metabolism in Arabidopsis thaliana
por: Noutoshi, Yoshiteru, et al.
Publicado: (2012)